Introduction
Multiple myeloma (MM) is at present an incurable B-lymphocyte neoplasia, characterized by slow proliferation of malignant-plasma cells (PC) in the bone-marrow (BM) [1] [2] [3] . Multiple antiapoptotic signaling mechanisms contribute to the accumulation of myeloma cells within the BM and account for their resistance to chemotherapy [4] [5] [6] . The most important molecules expressed by myeloma cells which promote their survival and proliferation are anti-apoptotic members of the BCL2 family and a number of growth factors, adhesion molecules and cytokines, especially IL6 [6] [7] [8] [9] . Several cytokines have also been reported to inhibit myeloma cell growth in different culture conditions, including bone morphogenetic proteins (BMPs) [10, 11] . Despite BMP proapoptotic action on several myeloma cell lines and primary myeloma cells in vitro [12] [13] [14] , other studies on different types of malignancies showed their tumor-promoting effects in vitro and in vivo [15] [16] [17] [18] [19] [20] . Importantly, in vitro effects of BMPs need to be further investigated on human MM samples because primary myeloma cells in culture conditions are removed from the interactions with other cells within BM microenvironment which may regulate their response [7] [8] [9] . In addition, primary myeloma cells have poor survival and growth in culture [21] , so the in vitro observations may not reveal the true biological role of BMPs in tumorigenesis.
BMPs, members of the transforming growth factor- superfamily, had been originally identified by their bone-inducing activity but were later shown to regulate a broad spectrum of cellular responses including proliferation, differentiation, morphogenesis, chemotaxis and apoptosis in a variety of cell types, including haematopoietic cells [22] [23] [24] . Although BMPs affect bone cells and thus may be relevant in MM bone disease [25] , we focused on direct BMP action on myeloma cells. BMPs exert their biological effects by signaling through both type I and II 5 serine/threonine kinase receptors and a family of intracellular signal transducers known as SMADs (small mothers against decapentaplegic) [22, 23] . The most common BMP intracellular signaling pathway is through the phosphorylation of SMAD1/5/8 complex, which translocates to the nucleus and either alone or in combination with other non-SMAD transcription factors regulate the transcription of target genes [23] . One of the important direct target of SMAD1/5/8 pathway in many cell systems is the inhibitor of DNA binding (ID) gene family [26] [27] [28] . ID genes encode a family of proteins that inhibit basics helix-loop-helix transcription factors to bind to DNA thus interrupting their regulatory role in many developmental and differentiation processes.
ID family were initially identified to inhibit cell differentiation, but more recently shown to have a much wider biological role in regulation of cell-cycle progression, migration and invasiveness.
Different studies on human tumors proved their oncogenic properties in regulating cell growth and proposed their causal role in malignant transformation, presumably through their deregulated expression caused by the perturbations in upstream signaling pathways [26] [27] [28] [29] [30] .
Whereas other studies on the effects of BMPs on myeloma cells have been performed only in vitro, this is the first report describing the expression pattern of BMPs, receptors and related molecules in human MM BM samples, as well as their potential clinical relevance as myeloma cell markers. In addition, by using myeloma cell lines we showed that BMPs protect myeloma cells from apoptosis induced by anti-myeloma drug bortezomib [31] or tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) [32] . Our results collectively indicate that BMPs promote myeloma cell survival by inducing ID family of oncogenes and increasing the ratio between pro-survival and pro-apoptotic molecules. 
Patients and Methods

Primary myeloma sample collection
After obtaining approval from the institutional Ethics Committee and informed consent from participants, we studied BM samples from 32 MM patients and 15 control subjects. Patients with MM were included in the study with a minimal diagnostic inclusion criterion of 10% malignant PC in cytologic or histologic BM specimen [33] , obtained as part of the routine clinical examination. Patients were assessed clinically for myeloma stage and bone disease [34] . Most patients entered the study at diagnosis (21/32), whereas a few had already been treated and assessed at relapse (8/32) or remission (3/32) ( Table 1 ). Patients were treated with different protocols adjusted for age and clinical status.
Fifteen BM samples, obtained from subjects (nine men and six women) without history of cancer, served as a control group; with median age 54 years (range 30-78). Most of the control BM samples (13/15) were collected from subjects assigned for BM aspiration as healthy donors and two were from patients aspirated for observation (one with leukocytosis and one with megaloblastic anemia). No statistical difference was found for age and sex between patient and control group. BM specimens were obtained by sterile punction of the iliac crest, followed by mononuclear cell separation using Histopaque (Sigma-Aldrich, St Louis, MO, USA). In selected samples, PC from BM aspirates were purified by immuno-magnetic separation using anti-CD138 antibodies (Caltag, Invitrogen Ltd, Paisley, UK) conjugated to magnetic beads (Dynal, Invitrogen Ltd) with the purity of >90% as confirmed by flow-cytometry. 
Cell culture
The human myeloma cell lines NCI H929 (DSMZ cell line collection, Brunschweig, Germany) and Theil (a gift from Dr. K. Pulford, University of Oxford, UK) were used for in vitro experiments. Cells were grown in RPMI 1640 supplemented with 10% fetal calf serum (FCS) (Gibco, Invitrogen Ltd), 2 mM L-glutamine and 100 U/ml penicillin/streptomycin, in a 5% CO 2 at 37C. Recombinant human (rh)BMP2, rhBMP4 or rhBMP6 (all from R&D Systems, Abingdon, UK) were used for the cell treatment as indicated in each experiment. In some experiments, the soluble BMP antagonist noggin (NOG) (PeproTech, London, UK) was used to anatagonize BMP effect, whereas bortezomib (a gift from Millenium Pharmaceuticals, Inc., Cambridge, MA, USA) and TRAIL (R&D Systems) were used to induce myeloma cell death and apoptosis. All experiments were repeated three times and the representative data were shown. 
Flow-cytometric analysis
Quantitative polymerase chain reaction amplification
(Hs00355782_m1), BAX (Hs00180269_m1) and GAPDH (Hs99999905_m1). Each reaction was performed in triplicate in a 25 L reaction volume using TaqMan Gene Expression Master Mix (Applied Biosystems), as recommended by the manufacturer. Cycle conditions were: incubation at 50°C for 2 minutes and at 95°C for 10 minutes, then 40 cycles of 15 s at 95°C and 60 s at 60°C. The relative quantities of unknown samples for the each gene were interpolated from the six-point dilution standard curve of the calibrator sample (BM cells or myeloma cell lines) as previously described [36] . To equalize samples according to the amount of input cDNA, the relative quantity of the target gene was normalized to GAPDH as the endogenous control.
Enzime-linked immunosorbent assay
Myeloma cells were solubilized in a lysis buffer for total proteins (1 mM EDTA, 0.5% Triton X-100 in 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ; pH 7.2-7.4) or phosphorylated proteins (1 mM EDTA, 0.5% Triton X-100, 10 mM NaF, 150 mM NaCl, 20 mM -glycerophosphate, 1 mM DTT; pH 7.2-7.4) containing protease inhibitors (Protease Inhibitor Cocktail Tablets; Roche). Total protein concentrations were determined in the supernatants of cell lyzates using a commercial kit (BCA protein assay; Pierce Biotechnology, Rockford, IL).
The concentration of phospho-TP53 (P53), BAX and BCL2 protein in cellular extracts was determined by ELISA using commercial kits (DuoSet IC; R&D Systems) according to the manufacturer's instructions. OD was determined on a microplate reader (Bio-Rad, Hercules, CA) set to 450 nm excitation wavelength. Protein concentration was interpolated from the seven-point dilution standard curve and expressed per mg total protein.
Statistics
Gene expression values between MM and control BM samples were expressed as median (range) and compared using non-parametric Mann-Whitey test. Values for RNA relative quantities and protein concentrations in cultured cell lines were expressed as meanSD and compared using analysis of variance (ANOVA). The receiver operating characteristic (ROC) curve analysis was expressed as area under curve (AUC) with its 95% confidence interval (CI) and used to determine the efficacy of analyzed genes to discriminate between MM and control group. Diagnostic efficacy for gene expression values were assessed through sensitivity and specificity at cut-off point. Gene expression values were correlated to clinical data using rank correlation and Spearman's coefficient of rank correlation rho () with its 95% CI. Statistical analysis was performed using MedCalc software-package (Mariakerke, Belgium). For all experiments, -level was set at 0.05.
Results
Expression of BMPs and related molecules in human multiple myeloma bone-marrow samples
Since it has been observed that BMPs modulate growth and survival of myeloma cells in vitro (Table 1 ) with 15 control BM samples by qPCR ( Table 2 , Fig 1A) . The expression of BMP4 and BMP6 was significantly higher in MM BM samples compared with control BM samples. BMP7 expression was below the detection limit of the qPCR assay in most samples.
We also analyzed the expression of several molecules involved in BMP signal transduction,
ACVR2A, ACVR2B, decoy receptor BAMBI (bone morphogenetic protein and activin membranebound inhibitor), intracellular signaling molecules -activatory SMAD5 and inhibitory SMAD6, BMP antagonist NOG, and inhibitors of DNA binding ID1 and ID2. Significant increase in the expression was found for ACVR1 and ACVR2A, both binding BMP6 [22] , whereas NOG expression was significantly down-regulated in MM BM samples compared with controls (Table   2 , Fig 1A) . BMPs may be produced by several cell types within the mononuclear fraction of BM cells [22] .
To identify the source of BMPs in MM BM samples, we analyzed the expression of BMPs and related molecules in purified CD138
+ malignant PC population of four MM BM samples obtained during routine clinical assessments (MM1, MM3 and MM4 at diagnosis and MM2 at progression; Table 3 ) and compared the expression pattern between the whole mononuclear fraction of MM BM aspirates, CD138  and CD138 + populations (Fig 2) . All samples expressed these molecules, albeit with high inter-individual variability ( Table 3 ). The lowest expression was detected in the sample MM1, which was obtained from the patient with the most benign disease stage. Most of the molecules were relatively over-expressed in CD138 + PC population compared with the whole BM aspirate, especially BMP4, BMP6 and ID1 (Fig 2) . This finding indicates that PC may be the source of BMPs and offers the potential clinical usefulness of BMPs as MM PC biomarkers.
Protection effect of BMPs on myeloma cells in vitro
Since we found significant over-expression of several BMPs and corresponding receptors in MM BM samples, we tested the effects of BMPs on myeloma cells in vitro. As primary myeloma cells are known for their poor ability to survive and divide in culture [21] , we investigated the mechanisms by which BMPs affect myeloma cells using myeloma cell lines. First we tested several myeloma cell lines (data not shown) and than used NCI H929 and Thiel cells to confirm the effect of BMPs on myeloma cell survival. Both MM cell lines expressed BMPs and corresponding receptors but to the very different extent (Fig 3) . The greatest difference was found for BMP7, BMPR1A and ACVR2B, which were over-expressed in NCI H929 cells, whereas BMP4, ACVR1 and ACVR2A were over-expressed in Thiel cells. Those differences may explain different response of cell lines to BMP treatment, seen after addition of bortezomib and TRAIL (Fig 4) .
When those cells were cultures for up to 72 hours with relatively high dose of BMP2, BMP4 or BMP6 (0.5 g/mL for all), in our experimental setting we could not induce significant changes in the proportion of dead and apoptotic cells determined by annexin V/PI staining and cell-cycle distribution (data not shown). Nevertheless, BMPs were able to partially protect myeloma cells from bortezomib-and TRAIL-induced apoptosis and increase cell survival, especially of bortezomib treated Thiel cells at earlier culture time-points (Fig 4) . 
Intracellular effects of BMPs on myeloma cell lines
We then analyzed the gene expression pattern of several groups of intracellular molecules, known to be important for myeloma cell survival, in order to determine the final effect of BMPs on myeloma cells, including tumor suppressor TP53 (P53) that transcriptionally regulate CDKN1A
(P21) and BAX [10], ID oncogenes [27], anti-apoptotic BCL2 [4] and growth factor IL6 [7] . We used BMP2 and BMP6 since they bind to different BMP receptors, whereas BMP2 and BMP4
overlap in receptor molecule usage [22] .
Treatment of Thiel cells with BMP2 or BMP6 (0.5 g/mL for both) for 24 hours produced weak effect on TP53 (data not shown), but significantly down-regulated CDKN1A and BAX, indicating pro-survival action (Fig 5A) . The expression of IL6, an autocrine and paracrine growth factor of myeloma cells [7] , was increased in Thiel cells with BMP6 ( Fig 5A) . Moreover, ID genes were induced by BMPs in both cell lines. Interestingly, NCI H929 cells, carrying t(4;14) translocation, had much higher constitutive expression of ID1, whereas Thiel plasma-blast cell line had lower TP53 and higher BCL2 constitutive expression (data not shown) as well as greater induction of ID genes by BMPs (Fig 5A) . In addition, we found that BMP treatment up-regulated the expression of extracellular BMP antagonist NOG and inhibitory transcription factor SMAD6 especially in Thiel cell line (Fig 5A) . Similar results of gene expression in myeloma cell lines were observed after BMP treatment for 12 h (data not shown). In a dose response experiments,
ID genes showed dose-dependent induction of expression by BMPs in Thiel cells (Fig 5B) .
Suppression of BMP induced gene expression of ID1 with BMP-specific soluble antagonist NOG (2 g/mL), confirmed that over-expression of ID genes was a specific effect of BMPs (Fig 5C) .
In addition to gene expression, we measured the concentration of phosphorylated TP53 by ELISA to assess the activation of transcription factor TP53 in NCI H929 and Thiel cells with 14 BMP2 or BMP6 (0.5 g/mL for both), but did not find significant effect within 12 hours upon treatment (data not shown). We also assessed the concentration of BCL2 and BAX, which has been shown to reciprocally regulate cell survival versus apoptosis [37, 38] . Addition of BMP2 or BMP6 did not change BCL2, but significantly decreased BAX concentration within 24 hours upon treatment (Fig 5D) . The final effect of BMP treatment was a 45% increase in the ratio of BCL2/BAX in Thiel cell line, indicating pro-survival effect.
Discussion
Other studies on the effects of BMPs on myeloma cells have been performed only in vitro, whereas the role of BMPs in tumorigenesis is still controversial. translocation that indicates poor prognosis [48] . Since ID1 enhanced proliferation and stimulated the invasiveness of several cancer cell types [29, 30] , it seems likely that malignant transformation reactivates proliferative machinery, temporarily inhibited in normal differentiated cells, through enhanced expression of ID genes [26] .
The unique effect of BMPs on myeloma cell lines, observed in our experimental setting, may be explained by the susceptibility of treated myeloma cells, determined by their intrinsic balance between pro-survival and pro-apoptotic factors. Induction of ID genes by BMPs was paralleled by the suppression of pro-apoptotic factors BAX and CDKN1A. Moreover, BMP treatment increased BCL2/BAX protein ratio, which has been recognized as a key indicator of suppressed apoptosis [37] . IL6, which promotes growth of myeloma cells and counteracts apoptotic signals by regulating BCL2 family [49] , was enhanced by BMP treatment in our conditions. It is known that resistance to apoptosis, common in myeloma cells, depends on activated intracellular pathways in the particular circumstances and constitutive expression of molecules acting at cellcycle checkpoints [6] [7] [8] [9] 23] . Relatively high basal apoptotic rate and the slow division of myeloma cells in culture may explain why BMPs exhibited the protective role on myeloma cell lines only in conditions of bortezomib-or TRAIL-induced apoptosis.
Conclusions
In inhibitor. BMP7 expression was below the detection limit of the qPCR assay in most samples.
2 Primary samples were obtained after the informed consent from patient with multiple myeloma (MM) and control subjects that were clinically observed for other reasons.
3 Comparisons with statistically significant difference (p<0.05) are bolded. 
